Skip to main content
Premium Trial:

Request an Annual Quote

Yuhan Licenses HER2 Inhibitor From J INTS Bio in $325M Deal

NEW YORK – Yuhan on Wednesday in-licensed J INTS Bio's HER2 targeted tyrosine kinase inhibitor, JIN-A04, in a deal potentially worth $325 million.

The license agreement includes a $1.9 million upfront payment to J INTS Bio, along with milestone payments based on future development, permits, and sales. JIN-A04 is being studied in preclinical studies to target HER2 exon 20 mutations in non-small cell lung cancer.

Seoul-based J INTS Bio is also developing several preclinical programs for NSCLC, including drugs targeting EGFR and HER2. The firm is also studying an HSP90 inhibitor and HDAC inhibitor for the treatment of glioblastoma.

Yuhan, also headquartered in Seoul, has one oncology product on the market in Korea, an EGFR inhibitor called Leclaza (lazertinib) for the treatment of NSCLC. The firm also has many immuno-oncology candidates in early-stage trials.

Yuhan previously invested $1.5 million in J INTS Bio and holds a 14.8 percent stake in the company.